Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Nanosciences Receives NIDDK Grant for NanoArrays

NEW YORK, April 15 - BioForce Nanosciences of Ames, Iowa, has received a $500,000 Phase I SBIR grant from the National Institute of Diabetes, Digestive, and Kidney diseases to build an antibody nanoarray for diagnostic tests using small sample volumes, the company said today.

 

This award, "Protein Nanoarray for Cytokine Profiling in Mouse Models", is one of  many SBIR grants that BioForce has received. Last July, the company was awarded a Phase II grant to further develop its nanoarray technology.

 

The company also has a collaboration with the NCI-FDA clinical proteomics program to develop nanoarrays. BioForce can currently fit a thousand spots within the space of a single ordinary microarrays spot.

 

Under this grant, the company will develop nanoarrays for protein profiling of cytokine biomarkers in diabetes, progressive renal failure, inflammatory bowel disease, and other kidney and digestive system diseases.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.